Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as successor. The company anticipates a strong FY27 launch calendar, particularly in the second half, with a focus on its "diabesity franchise." Significant debt reduction has been achieved, with further operational cash flow prioritized for additional deleveraging.